Search research articles
Contact Us
Filters
Showing results (241-250 of 289) with videos related to
Page
of 29
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2015
Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis
I Fleury, S Chevret, M Pfreundschuh, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
March 29, 2002
Assessing the Cox model assumption as a statistical tool for classifying lymphomas
P Morel, B Souleau, F Morschhauser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 18, 2003
Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab
P Feugier, J M Virion, H Tilly, et al.
La Semaine Des Hopitaux : Organe Fonde Par L'Association D'Enseignement Medical Des Hopitaux De Paris
|
January 21, 1982
[An empirical combination of antibiotics used in aplasias during chemotherapy for acute malignant hemopathies (author's transl)]
D Fiere, H Vuvan, D Guyotat, et al.
Bone Marrow Transplantation
|
January 1, 1991
The Parma international randomized study in relapsed non Hodgkin lymphoma: 1st interim analysis of 128 patients (as 15 January 1991: 153 patients)
A Hagenbeek, T Philip, D Bron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2000
Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group
P Brice, M Divine, D Simon, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
March 29, 2002
Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma
A Bosly, E Lepage, B Coiffier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 17, 2010
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
F Morschhauser, P Marlton, U Vitolo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 9, 2000
Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response
J M Foran, D Cunningham, B Coiffier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1996
Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte
M Diviné, E Lepage, J Brière, et al.
Page
of 29
Search research articles
Search
Showing results (241-250 of 289) with videos related to
Sort By:
Page
of 29
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2015
Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis
I Fleury, S Chevret, M Pfreundschuh, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
March 29, 2002
Assessing the Cox model assumption as a statistical tool for classifying lymphomas
P Morel, B Souleau, F Morschhauser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 18, 2003
Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab
P Feugier, J M Virion, H Tilly, et al.
La Semaine Des Hopitaux : Organe Fonde Par L'Association D'Enseignement Medical Des Hopitaux De Paris
|
January 21, 1982
[An empirical combination of antibiotics used in aplasias during chemotherapy for acute malignant hemopathies (author's transl)]
D Fiere, H Vuvan, D Guyotat, et al.
Bone Marrow Transplantation
|
January 1, 1991
The Parma international randomized study in relapsed non Hodgkin lymphoma: 1st interim analysis of 128 patients (as 15 January 1991: 153 patients)
A Hagenbeek, T Philip, D Bron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2000
Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group
P Brice, M Divine, D Simon, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
March 29, 2002
Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma
A Bosly, E Lepage, B Coiffier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 17, 2010
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
F Morschhauser, P Marlton, U Vitolo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 9, 2000
Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response
J M Foran, D Cunningham, B Coiffier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1996
Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte
M Diviné, E Lepage, J Brière, et al.
Page
of 29